vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Mistras Group, Inc. (MG). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $181.5M, roughly 1.1× Mistras Group, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 5.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -0.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
AXSM vs MG — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $181.5M |
| Net Profit | — | $3.8M |
| Gross Margin | — | 28.4% |
| Operating Margin | -33.1% | 7.0% |
| Net Margin | — | 2.1% |
| Revenue YoY | 57.4% | 5.1% |
| Net Profit YoY | — | -27.4% |
| EPS (diluted) | — | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $181.5M | ||
| Q3 25 | $171.0M | $195.5M | ||
| Q2 25 | $150.0M | $185.4M | ||
| Q1 25 | $121.5M | $161.6M | ||
| Q4 24 | $118.8M | $172.7M | ||
| Q3 24 | $104.8M | $182.7M | ||
| Q2 24 | $87.2M | $189.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $3.8M | ||
| Q3 25 | $-47.2M | $13.1M | ||
| Q2 25 | $-48.0M | $3.0M | ||
| Q1 25 | $-59.4M | $-3.2M | ||
| Q4 24 | $-74.9M | $5.2M | ||
| Q3 24 | $-64.6M | $6.4M | ||
| Q2 24 | $-79.3M | $6.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 28.4% | ||
| Q3 25 | — | 29.8% | ||
| Q2 25 | — | 29.1% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 26.5% | ||
| Q3 24 | — | 26.8% | ||
| Q2 24 | — | 27.1% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 7.0% | ||
| Q3 25 | -27.0% | 10.4% | ||
| Q2 25 | -24.5% | 4.5% | ||
| Q1 25 | -46.9% | -0.6% | ||
| Q4 24 | -61.1% | 6.1% | ||
| Q3 24 | -59.8% | 6.5% | ||
| Q2 24 | -89.5% | 6.3% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 2.1% | ||
| Q3 25 | -27.6% | 6.7% | ||
| Q2 25 | -32.0% | 1.6% | ||
| Q1 25 | -48.9% | -2.0% | ||
| Q4 24 | -63.1% | 3.0% | ||
| Q3 24 | -61.7% | 3.5% | ||
| Q2 24 | -91.0% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.12 | ||
| Q3 25 | $-0.94 | $0.41 | ||
| Q2 25 | $-0.97 | $0.10 | ||
| Q1 25 | $-1.22 | $-0.10 | ||
| Q4 24 | $-1.54 | $0.17 | ||
| Q3 24 | $-1.34 | $0.20 | ||
| Q2 24 | $-1.67 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $28.0M |
| Total DebtLower is stronger | $70.0M | $178.0M |
| Stockholders' EquityBook value | — | $235.1M |
| Total Assets | $713.6M | $578.8M |
| Debt / EquityLower = less leverage | — | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $28.0M | ||
| Q3 25 | $325.3M | $27.8M | ||
| Q2 25 | $303.0M | $20.0M | ||
| Q1 25 | $300.9M | $18.5M | ||
| Q4 24 | $315.4M | $18.3M | ||
| Q3 24 | $327.3M | $20.4M | ||
| Q2 24 | $315.7M | $17.2M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $178.0M | ||
| Q3 25 | — | $202.3M | ||
| Q2 25 | — | $189.4M | ||
| Q1 25 | — | $171.9M | ||
| Q4 24 | — | $169.6M | ||
| Q3 24 | — | $189.7M | ||
| Q2 24 | — | $199.7M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $235.1M | ||
| Q3 25 | $73.7M | $227.4M | ||
| Q2 25 | $73.1M | $215.8M | ||
| Q1 25 | $53.2M | $198.7M | ||
| Q4 24 | $57.0M | $198.6M | ||
| Q3 24 | $92.9M | $205.2M | ||
| Q2 24 | $102.9M | $193.2M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $578.8M | ||
| Q3 25 | $669.3M | $596.3M | ||
| Q2 25 | $639.8M | $571.0M | ||
| Q1 25 | $596.7M | $526.8M | ||
| Q4 24 | $568.5M | $523.0M | ||
| Q3 24 | $561.5M | $551.7M | ||
| Q2 24 | $548.2M | $548.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.85× | ||
| Q3 24 | — | 0.92× | ||
| Q2 24 | — | 1.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $32.1M |
| Free Cash FlowOCF − Capex | — | $26.0M |
| FCF MarginFCF / Revenue | — | 14.3% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | 8.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $8.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $32.1M | ||
| Q3 25 | $1.0M | $4.5M | ||
| Q2 25 | $-32.4M | $-9.3M | ||
| Q1 25 | $-43.4M | $5.6M | ||
| Q4 24 | $-26.2M | $25.7M | ||
| Q3 24 | $-18.6M | $19.4M | ||
| Q2 24 | $-30.1M | $4.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $26.0M | ||
| Q3 25 | $988.0K | $-4.1M | ||
| Q2 25 | $-32.4M | $-14.7M | ||
| Q1 25 | $-43.7M | $1.1M | ||
| Q4 24 | $-26.2M | $22.1M | ||
| Q3 24 | $-18.7M | $14.6M | ||
| Q2 24 | $-30.2M | $-284.0K |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 14.3% | ||
| Q3 25 | 0.6% | -2.1% | ||
| Q2 25 | -21.6% | -7.9% | ||
| Q1 25 | -36.0% | 0.7% | ||
| Q4 24 | -22.1% | 12.8% | ||
| Q3 24 | -17.9% | 8.0% | ||
| Q2 24 | -34.6% | -0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.4% | ||
| Q3 25 | 0.0% | 4.4% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.3% | 2.8% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.1% | 2.6% | ||
| Q2 24 | 0.1% | 2.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.55× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | -3.07× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.96× | ||
| Q3 24 | — | 3.02× | ||
| Q2 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
MG
Segment breakdown not available.
